|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,596 GBX | -0.50% |
|
-1.20% | +10.43% |
| Jun. 13 | REGENXBIO Inc. Announces Chief Executive Officer Changes | CI |
| Jun. 12 | Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says | MT |
Oct 1 (Reuters) - GlaxoSmithKline and Medicago:
* MEDICAGO TO LAUNCH CLINICAL TRIALS FOR COVID-19 VACCINE CANDIDATE WITH GSK'S PANDEMIC ADJUVANT IN JAPAN
* MEDICAGO’S COVID-19 VACCINE CANDIDATE HAS NOW COMPLETED ENROLLMENT OF ITS PHASE 2/3 CLINICAL TRIALS
* STUDY, WITH FINAL DATA FROM GLOBAL PHASE 2/3 STUDY OF VACCINE CANDIDATE, TO BE USED TO SUPPORT APPLICATION FOR APPROVAL IN JAPAN BY MARCH OF 2022. Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| +10.43% | 82.98B | |
| +41.87% | 630B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +18.02% | 246B | |
| +0.57% | 225B | |
| +10.71% | 218B | |
| +3.68% | 160B | |
| -4.38% | 156B |
GSK PLC 
